Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, Zealand Pharma announced phase II results regarding obesity, several companies announced their first quarter results and some got their price targets hiked.
10 of the 20 listed, Danish biotech companies have published news the past week. 10 of the companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Fluoguide AB has been the best performing stock this year with Y-mAbs continuing recoveing lost ground.
Company news the past week
Ascendis Pharma
Wedbush cuts target to 186USD from 195USD and BOFA raises to 107 USD from 92 USD.
Biosergen publishes 2022 annual report (Link)
Cessatech
First quarter report Q1-2023 (Link)
CS MEDICA Announces Positive Results from Clinical Trial of Nasal Protect Gel for Hay Fever/Allergic Rhinitis (Link)
CS MEDICA A/S exhibits at the leading event Vitafoods Europe with suppliers and experts from over 100 countries today (Link)
No news the past week
Evaxion Biotech
No news the past week
Expres2ion
No news the past week
Fluoguide
No news the past week
Genmab
GENMAB ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2023 (Link)
Updated price targets (DKK): Jeffries raises to 2900 from 2850, BOFA raises to 3385 from 3310 and JP Morgan cuts its target from 3400 to 3200.
Gubra
Gubra posts 19% CRO revenue growth in Q1 2023. Full-year 2023 outlook maintained (Link)
Initiator Pharma
No news the past week
IO Biotech
IO Biotech Announces 2023 First-Quarter Results (Link)
H.C. WAINWRIGHT RAISES TARGET PRICE TO $11 FROM $10
Pila Pharma
No news the past week
Saniona
No news the past week
Scandion Oncology
No news the past week
SynAct Pharma
No news the past week
ViroGates
No news the past week
Zealand Pharma
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight (Link)
Zealand Pharma Announces Financial Results for the First Quarter of 2023 (Link)
Y-mAbs Therapeutics
Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance (Link)
Wedbush raises price target to 13 USD from 5 USD
2cureX
Positive IndiTreat® trial results published in highly recognized scientific journal (Link)
SELECTED CASES
SHARE PRICE DEVELOPMENTS
The Danish Biotech stocks showed good performance last week. The average return was 2%. Y-mAbs Therapeutics Inc. rose 30% after they posted first quater results. On the other hand, ViroGates A/S and Gubra A/S became the worst performing Danish biotech stocks last week falling 11%. Since the start of the year, most of the companies have delivered a negative return. However, the average return year-to-date is positive at 8% because a few companies as especially Y-mAbs Therapeutics Inc, Zealand Pharma A/S, Fluoguide AB and Saniona AB have done really well.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
Overview of share price developments the past week, year-to-date and last twelve months
